You are using an outdated browser. Please upgrade your browser to improve your experience.

aldesleukin

a recombinant human IL-2, marketed for the treatment of metastatic renal cell carcinoma; BAY 50-4798 is a variant
Target Activities
Items per page:
10
1 – 3 of 3